Meeting
2018 ASCO Annual Meeting
Induction chemoradiotherapy for esophageal cancer: Comparing CROSS regimen with cisplatin/5-FU.
Authors
Abraham Geller
Harvard Medical School, Boston, MA
Abraham Geller , Ashok Muniappan , Hui Zheng , Henning A Gaissert , Cameron D Wright , Douglas J Mathisen , Michael Lanuti
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Esophageal or Gastric Cancer
Citation
J Clin Oncol 36, 2018 (suppl; abstr 4070)
DOI
10.1200/JCO.2018.36.15_suppl.4070
Abstract #
4070
Poster Bd #
259
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Survival outcomes from CALGB 80803 (Alliance): A randomized phase II trial of PET scan-directed combined modality therapy for esophageal cancer.
First Author: Karyn A. Goodman
Poster
2017 Gastrointestinal Cancers Symposium
Influence of tumor response and treatment schedule on the distribution of tumor recurrence in esophageal cancer patients treated with neoadjuvant chemoradiotherapy.
First Author: Kristien M. Jipping
Poster
2022 ASCO Annual Meeting
Preoperative chemoradiation (CRT) with carboplatin (CBP)/paclitaxel (PCL) (CP) or with 5-fluorouracil (FU)/oxaliplatin (OX) (Fx) for esophageal or junctional cancer: A randomized phase 2 trial.
First Author: Antoine Adenis
Poster
2017 ASCO Annual Meeting
Comparison of chemoradiotherapy (CRT) using carboplatin/paclitaxel (CP) versus cisplatin/5-FU (CF) for esophageal or gastroesophageal junctional (GEJ) cancer.
First Author: Hao-Wen Sim